RS51140B - Derivati imidazolidina, njihovo dobijanje i njihova upotreba kao antiinflamatornih agensa - Google Patents
Derivati imidazolidina, njihovo dobijanje i njihova upotreba kao antiinflamatornih agensaInfo
- Publication number
- RS51140B RS51140B YUP-708/03A YUP70803A RS51140B RS 51140 B RS51140 B RS 51140B YU P70803 A YUP70803 A YU P70803A RS 51140 B RS51140 B RS 51140B
- Authority
- RS
- Serbia
- Prior art keywords
- alkoxy
- alkyl
- phenyl
- amino
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Jedinjenje formule I, naznačeno time,što jeA, ciklopropilmetil- ili izobutil; E je -CO-R6, -CO-H ili -CH2-OR7; Z je kiseonik ili sumpor; R1 je vodonik ili metil;R2 je fenil, piridil ili (C1-C4)-alkil, pri čemu je alkil ostatak koji može biti supstituisan jednim ili više atomima fluora, a fenil ostatak može biti supstituisan jednim ili više identičnih ili različitih supstituenata odabranih iz grupe koju čine (C1-C4)-alkil, (C1-C4)-alkoksi, metilendioksi, etilendioksi, halogen, trifiuorometil i trifiuorometoksi; R3 i R4 su metil ili trifluormetil;R5 je vodonik ili (C1-C4)-alkil, pri čemu je alkil ostatak koji može biti supstituisan jednim ili više atomima fluora;R6 je hidroksil, (C1-C10)-alkoksi, fenil-(C1-C8)-alkoksi, feniloksi, (C1-C8)-alkilkarboniloksi- (C1-C6)-alkoksi, fenilkarboniloksi-(C1-C6)-alkoksi, fenil-(C1-C6)-alkilkarboniloksi-(C1-C6)-alkoksi, (C1-C8)-alkoksikarboniloksi-(C1-C6)-alkoksi, feniloksikarboniloksi-(C1-C6)-alkoksi, fenil-(C1-C6)-alkoksikarboniloksi-(C1-C6)-alkoksi, amino, mono ((C1-C10)-alkil)amino ili di((C1-C10)-alkil)amino; R7 je vodonik ili (C1-C4)-alkil;i svi njihovi steroizomerni oblici i njihove smeše u svim odnosima, i njihovi fiziološki prihvatljive soli.Prijava sadrži još 15 patentnih zahteva.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10111877A DE10111877A1 (de) | 2001-03-10 | 2001-03-10 | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| YU70803A YU70803A (sh) | 2006-05-25 |
| RS51140B true RS51140B (sr) | 2010-10-31 |
Family
ID=7677184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YUP-708/03A RS51140B (sr) | 2001-03-10 | 2002-02-23 | Derivati imidazolidina, njihovo dobijanje i njihova upotreba kao antiinflamatornih agensa |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US6680333B2 (sr) |
| EP (1) | EP1373249B1 (sr) |
| JP (1) | JP4482277B2 (sr) |
| KR (1) | KR100991678B1 (sr) |
| CN (1) | CN1227248C (sr) |
| AR (1) | AR035692A1 (sr) |
| AT (1) | ATE293621T1 (sr) |
| AU (1) | AU2002233358B2 (sr) |
| BG (1) | BG108134A (sr) |
| BR (1) | BR0207981A (sr) |
| CA (1) | CA2440648C (sr) |
| CZ (1) | CZ301893B6 (sr) |
| DE (2) | DE10111877A1 (sr) |
| DK (1) | DK1373249T3 (sr) |
| EE (1) | EE05401B1 (sr) |
| ES (1) | ES2240687T3 (sr) |
| HK (1) | HK1062173A1 (sr) |
| HR (1) | HRP20030713B1 (sr) |
| HU (1) | HU228304B1 (sr) |
| IL (2) | IL157830A0 (sr) |
| ME (1) | MEP61108A (sr) |
| MX (1) | MXPA03007634A (sr) |
| MY (1) | MY129029A (sr) |
| NO (1) | NO326001B1 (sr) |
| NZ (1) | NZ528075A (sr) |
| PE (1) | PE20020904A1 (sr) |
| PL (1) | PL204622B1 (sr) |
| PT (1) | PT1373249E (sr) |
| RS (1) | RS51140B (sr) |
| RU (1) | RU2303592C2 (sr) |
| SI (1) | SI1373249T1 (sr) |
| SK (1) | SK286652B6 (sr) |
| TW (1) | TWI328587B (sr) |
| WO (1) | WO2002072573A1 (sr) |
| ZA (1) | ZA200306107B (sr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19647380A1 (de) * | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
| AU3906300A (en) * | 1999-03-22 | 2000-10-09 | Ortho-Mcneil Pharmaceutical, Inc. | Process of preparing 3s-3-amino-3-aryl propionic acid and derivatives thereof |
| EP1674100A4 (en) * | 2003-10-10 | 2010-04-14 | Kowa Co | INHIBITOR OF ANGIOGENESIS |
| CA2723358A1 (en) * | 2008-05-05 | 2009-11-12 | Allison B. Reiss | Method for improving cardiovascular risk profile of cox inhibitors |
| WO2012061074A1 (en) | 2010-10-25 | 2012-05-10 | Elan Pharmaceuticals, Inc. | METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS |
| CN112707874A (zh) * | 2020-12-29 | 2021-04-27 | 广东中科药物研究有限公司 | 一种抗病毒化合物及其制备方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4009506A1 (de) | 1990-03-24 | 1991-09-26 | Hoechst Ag | Hydantoinderivate |
| DE4126277A1 (de) | 1991-08-08 | 1993-02-11 | Cassella Ag | Hydantoinderivate |
| ES2102009T5 (es) | 1992-01-13 | 2004-12-16 | Biogen Inc | Tratamiento para el asma. |
| AU674302B2 (en) | 1992-02-12 | 1996-12-19 | Biogen Idec Ma Inc. | Treatment for inflammatory bowel disease |
| DE4207254A1 (de) | 1992-03-07 | 1993-09-09 | Cassella Ag | 4-oxo-2-thioxoimidazolidin-derivate |
| DE4213634A1 (de) | 1992-04-24 | 1993-10-28 | Cassella Ag | 2,4-Dioxo-imidazolidin-Derivate |
| DE4224414A1 (de) | 1992-07-24 | 1994-01-27 | Cassella Ag | Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung |
| DE4228717A1 (de) | 1992-08-28 | 1994-03-03 | Cassella Ag | Imidazolidin-Derivate |
| CA2153228A1 (en) | 1993-01-08 | 1994-07-21 | Shiu-Lan Ng Chiang | Peptide inhibitors of cell adhesion |
| DE69419721T2 (de) | 1993-01-12 | 2000-04-27 | Biogen, Inc. | Rekombinante anti-vla4 antikörpermoleküle |
| NZ262615A (en) | 1993-02-09 | 1996-02-27 | Biogen Inc | Treating insulin dependent diabetes (type i) with anti vla4 (very late antigen) antibodies |
| DE4308034A1 (de) | 1993-03-13 | 1994-09-15 | Cassella Ag | Neue Heterocyclen, ihre Herstellung und ihre Verwendung |
| DE4427979A1 (de) | 1993-11-15 | 1996-02-15 | Cassella Ag | Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung |
| AU693143B2 (en) | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| EP0804237B8 (en) | 1994-01-25 | 2006-11-08 | Elan Pharmaceuticals, Inc. | Humanized antibodies against leukocyte adhesion molecule vla-4 |
| AU2958195A (en) | 1994-06-29 | 1996-01-25 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin |
| US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
| GB9524630D0 (en) | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| DE19515177A1 (de) | 1995-04-28 | 1996-10-31 | Cassella Ag | Hydantoinderivate als Zwischenprodukte für pharmazeutische Wirkstoffe |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| EP0796855B1 (de) | 1996-03-20 | 2002-02-06 | Hoechst Aktiengesellschaft | Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| EP0917462B1 (en) | 1996-07-25 | 2006-09-13 | Biogen Idec MA Inc. | Cell adhesion inhibitors |
| DE19647381A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
| PL323130A1 (en) | 1996-11-15 | 1998-05-25 | Hoechst Ag | Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such |
| DE19647380A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
| WO1998042656A1 (en) | 1997-03-21 | 1998-10-01 | Cytel Corporation | Novel compounds |
| DE19741235A1 (de) | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19741873A1 (de) | 1997-09-23 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| AU748041B2 (en) | 1997-10-31 | 2002-05-30 | Aventis Pharma Limited | Substituted anilides |
| GB9723789D0 (en) * | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Chemical compounds |
| DE19751251A1 (de) * | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
| WO1999054321A1 (en) | 1998-04-21 | 1999-10-28 | Aventis Pharma Limited | Substituted diamines and their use as cell adhesion inhibitors |
| DE19821483A1 (de) * | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| YU77600A (sh) * | 1998-06-30 | 2004-03-12 | Pfizer Products Inc. | Nepeptidni inhibitori vla-4 zavisnog ćelijskog vezivanja koji su primenljivi u tretiranju inflamatornih, autoimunih i respiratornih oboljenja |
| WO2000002903A1 (en) | 1998-07-10 | 2000-01-20 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
| DE19922462A1 (de) * | 1999-05-17 | 2000-11-23 | Aventis Pharma Gmbh | Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate |
-
2001
- 2001-03-10 DE DE10111877A patent/DE10111877A1/de not_active Withdrawn
-
2002
- 2002-02-23 PL PL362573A patent/PL204622B1/pl unknown
- 2002-02-23 DK DK02700268T patent/DK1373249T3/da active
- 2002-02-23 AT AT02700268T patent/ATE293621T1/de active
- 2002-02-23 SK SK1126-2003A patent/SK286652B6/sk not_active IP Right Cessation
- 2002-02-23 RU RU2003129986/04A patent/RU2303592C2/ru not_active IP Right Cessation
- 2002-02-23 CA CA2440648A patent/CA2440648C/en not_active Expired - Fee Related
- 2002-02-23 ME MEP-611/08A patent/MEP61108A/xx unknown
- 2002-02-23 BR BR0207981-0A patent/BR0207981A/pt active Search and Examination
- 2002-02-23 PT PT02700268T patent/PT1373249E/pt unknown
- 2002-02-23 RS YUP-708/03A patent/RS51140B/sr unknown
- 2002-02-23 SI SI200230124T patent/SI1373249T1/xx unknown
- 2002-02-23 DE DE60203791T patent/DE60203791T2/de not_active Expired - Lifetime
- 2002-02-23 MX MXPA03007634A patent/MXPA03007634A/es active IP Right Grant
- 2002-02-23 CZ CZ20032429A patent/CZ301893B6/cs not_active IP Right Cessation
- 2002-02-23 EE EEP200300436A patent/EE05401B1/xx not_active IP Right Cessation
- 2002-02-23 CN CNB028063147A patent/CN1227248C/zh not_active Expired - Fee Related
- 2002-02-23 HU HU0303455A patent/HU228304B1/hu not_active IP Right Cessation
- 2002-02-23 NZ NZ528075A patent/NZ528075A/en not_active IP Right Cessation
- 2002-02-23 IL IL15783002A patent/IL157830A0/xx unknown
- 2002-02-23 WO PCT/EP2002/001917 patent/WO2002072573A1/en active IP Right Grant
- 2002-02-23 EP EP02700268A patent/EP1373249B1/en not_active Expired - Lifetime
- 2002-02-23 KR KR1020037011940A patent/KR100991678B1/ko not_active IP Right Cessation
- 2002-02-23 AU AU2002233358A patent/AU2002233358B2/en not_active Ceased
- 2002-02-23 JP JP2002571489A patent/JP4482277B2/ja not_active Expired - Fee Related
- 2002-02-23 ES ES02700268T patent/ES2240687T3/es not_active Expired - Lifetime
- 2002-03-07 AR ARP020100830A patent/AR035692A1/es active IP Right Grant
- 2002-03-08 PE PE2002000184A patent/PE20020904A1/es not_active Application Discontinuation
- 2002-03-08 TW TW091104327A patent/TWI328587B/zh not_active IP Right Cessation
- 2002-03-08 US US10/092,901 patent/US6680333B2/en not_active Expired - Lifetime
- 2002-03-08 MY MYPI20020824A patent/MY129029A/en unknown
-
2003
- 2003-08-07 ZA ZA200306107A patent/ZA200306107B/en unknown
- 2003-08-25 BG BG108134A patent/BG108134A/bg unknown
- 2003-09-08 HR HR20030713A patent/HRP20030713B1/xx not_active IP Right Cessation
- 2003-09-09 NO NO20033981A patent/NO326001B1/no not_active IP Right Cessation
- 2003-09-09 IL IL157830A patent/IL157830A/en not_active IP Right Cessation
-
2004
- 2004-06-11 HK HK04104237A patent/HK1062173A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS50378B (sr) | N-heterociklični derivati kao nos inhibitori | |
| HRP20050390A2 (en) | Substituted benzoxazinones and uses thereof | |
| MXPA04001240A (es) | Analogos antitumorales. | |
| HUP0300434A2 (hu) | Oxazolszármazékok és alkalmazásuk tirozin-kináz-inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| BRPI0616799B8 (pt) | derivado de piridina e derivado de pirimidina, composições farmacêuticas, usos, inibidores de angiogênese, contra receptor de fator de crescimento de hepatócito e contra metástase de câncer, e agente antitumor | |
| MEP25608A (en) | Derivatives of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics | |
| DE60130771D1 (de) | Substituierte heterocyclische amide | |
| HRP20070510T3 (en) | Benzimidazole derivative and its use as a ii receptor antagonist | |
| HRP20040429B1 (en) | Sulphonamide derivatives, the preparation thereof and the application of same as medicaments | |
| CA2318349A1 (en) | Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use | |
| MY146669A (en) | Pyrazole derivatives for treating hiv | |
| RS20050182A (en) | Derivatives of dioxane-2-alkyl carbamates,preparation method thereof and application of same in therapeutics | |
| HK1068334A1 (en) | Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments | |
| HUP0204399A2 (en) | Pteridine compounds for the treatment of psoriasis, process for their preparation, pharmaceutical compositions containing them and their use | |
| RS52562B (sr) | (3-aril-piperazin-1-il) derivati 6,7-dialkoksikvinazolina, 6,7- dialkoksiftalazina i 6,7-dialkoksiizokvinolina | |
| MXPA05011411A (es) | 1,4-diazepinas sustituidas y usos de las mismas. | |
| RS51200B (sr) | (imidazol-1-il-metil)-piridazin kao blokator nmda receptora | |
| RS50829B (sr) | Novi oligosaharidi, njihova proizvodnja i farmaceutske kompozicije sa sadržajem istih | |
| HRP20070286T3 (en) | Substituted diketopiperazines and their use as oxytocyn antagonists | |
| HK1081194A1 (en) | 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof | |
| HUP0203184A2 (hu) | Izoxazolkarboxamid-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| RS51190B (sr) | Aminoacilni derivati kao prolekovi i lekovi za lečenje tromboembolijskih bolesti | |
| BRPI0417345A (pt) | compostos inibidores de quìnase baseados em azola, composições e seus usos | |
| HRP20080119T3 (en) | Benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same | |
| HRP20040230B1 (en) | Muscarinic agonists |